Research note — 8 August 2026. Educational only, not investment advice. Verify final offer data in the RHP.
Executive view
Molbio is the most differentiated technology story in this group. Its Truenat platform moves real-time PCR molecular testing closer to the point of care, with an installed-base/assay-consumable model that could be structurally more attractive than a plain diagnostic distributor. The company says it has touched 40+ million lives across 85+ countries, and its Bigtec Labs subsidiary underpins research and development. The investment issue is not whether the technology is interesting; it is whether recurring consumables, tender concentration and regulatory exposure support the price paid.
Offer lens
| Reported band | INR 768–807 |
|---|---|
| Reported retail lot | 18 shares |
| Reported issue size | Approximately INR 939.7 crore |
| Reported split | Approximately INR 200 crore fresh; INR 739.7 crore OFS |
A high OFS share means the offer is substantially a liquidity event for selling holders. The future economics therefore need to be compelling without assuming that the primary capital itself will create the whole investment case.
Reported growth
Market materials report FY26 revenue of approximately INR 1,455.2 crore and PAT of INR 164.1 crore, following approximately INR 1,028 crore revenue and INR 138.6 crore PAT in FY25. That is an approximately 11.3% FY26 net margin. Before relying on it, reconcile it to the restated RHP financials and distinguish three streams: instrument/platform sales, test kits/consumables and service/other income.
The central economic question
Equipment sales can be lumpy and tender-driven. Consumables used on an installed platform can be recurring, higher visibility and potentially higher margin. The quality of the earnings stream is therefore determined by: installed-base size; tests per instrument; assay menu; repeat procurement; customer switching cost; pricing; and maintenance/service obligations. The best outcome is a growing installed base with rising utilisation that creates a durable consumables annuity. The weaker outcome is periodic instrument/tender demand that makes revenue volatile.
Risks to examine
- Tender and policy concentration: public-health programmes can be large and mission-critical but may have long payment cycles, renewals and price pressure.
- Regulatory exposure: diagnostic approval, quality systems, country-specific registrations and post-market obligations can limit market access.
- Geography and FX: exports diversify demand but introduce receivable, currency, distributor and geopolitical risk.
- Competitive response: central laboratories, alternative point-of-care platforms and local procurement rules can affect pricing and share.
- Working capital: inventory of instruments/kits and tender receivables should be tested against operating cash flow.
Valuation discipline
Do not pay a technology-platform multiple for equipment revenue alone. Build separate revenue/margin assumptions for installed systems, consumables and service; then stress a lower test-per-instrument rate and tender-price pressure. The company’s differentiation can justify a premium only if recurring revenue, gross margin and cash collections prove as durable as the technology narrative.
Conclusion
Molbio deserves a close look because its product architecture may have a defensible installed-base economics. But the investment-grade evidence is in the RHP tables: mix, utilisation, customer/geographic concentration, pricing and cash conversion. The decision should turn on those facts, not on the understandable appeal of the health-tech theme.